Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
Status:
Terminated
Trial end date:
1989-03-01
Target enrollment:
Participant gender:
Summary
This study compares three different therapies for treatment of refractory Pneumocystis
carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed
to respond to at least 4 days of treatment with either of two standard therapies: (1)
sulfamethoxazole/trimethoprim (SMX/TMP) or (2) pentamidine (PEN). This study compares therapy
with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus
high-dose steroids (methylprednisolone). The purpose is to find better and safer forms of
treatment for PCP in AIDS patients. There is at present no scientific information about the
best treatment for an AIDS patient with PCP who is not improving while receiving the standard
therapies (SMX/TMP or PEN). New drug treatments are available, including steroid therapy and
TMTX, but there is no information proving that these new treatments work better than the
standard therapies.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)